Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep;101(9):1931-1940.
doi: 10.1007/s00277-022-04901-z. Epub 2022 Jul 27.

Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis

Nadirah El-Amin  1 , Audra Iness  2 , John W Cyrus  3 , India Sisler  1 , Oliver Karam  4
Affiliations
Meta-Analysis

Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis

Nadirah El-Amin et al. Ann Hematol. 2022 Sep.

Abstract

Sickle cell disease (SCD) results in many complications including an increased risk of developing venous thromboembolic events (VTEs) and an increased risk of mortality as a result. We conducted a systematic review using multiple databases to compare the efficacy of different anticoagulation in preventing recurrence, development of bleeding, progression of thrombus, and mortality in patients with SCD and a venous thrombotic event. Eight hundred seventy-one studies were screened and six studies were included. Among patients with SCD who experienced a VTE and were anticoagulated, the overall recurrence of VTE was 27.6% (95%CI 23.5-31.9). The overall progression to pulmonary embolism (PE) was 11.7% (95%CI 4.3-22.1). The overall bleeding rate was 14.1% (95%CI 7.8-21.9) and the overall mortality was 3.7% (95%CI 0.8-8.5). Based on observational studies, there did not appear to be differences between anticoagulant classes for the above adverse outcomes. Significant heterogeneity in the patient population and outcome measures limited the interpretation of the results. More studies, specifically randomized trials, are needed to help direct appropriate management of VTE's in patients with sickle cell disease (PROSPERO ID: 236,208).

Keywords: Anemia, Sickle cell; Anticoagulants; Assessment, Health care; Hemorrhage; Venous thromboembolism.

PubMed Disclaimer

References

    1. Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561–1573. https://doi.org/10.1056/NEJMra1510865 - DOI - PubMed
    1. Pinto VM, Balocco M, Quintino S, Forni GL (2019) Sickle cell disease: a review for the internist. Intern Emerg Med 14:1051–1064. https://doi.org/10.1007/s11739-019-02160-x - DOI - PubMed
    1. Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol 14:263–292. https://doi.org/10.1146/annurev-pathmechdis-012418-012838 - DOI - PubMed
    1. Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S (2013) Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 126:443–449. https://doi.org/10.1016/j.amjmed.2012.12.016 - DOI - PubMed - PMC
    1. Noubouossie D, Key NS, Ataga KI (2016) Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev 30:245–256. https://doi.org/10.1016/j.blre.2015.12.003 - DOI - PubMed

MeSH terms

LinkOut - more resources